8158 On Other Exchanges
Symbol
Exchange
8158 is not on other exchanges.

china regenerative medicine (8158) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA REGENERATIVE MEDICINE (8158)

Related News

No related news articles were found.

china regenerative medicine (8158) Related Businessweek News

No Related Businessweek News Found

china regenerative medicine (8158) Details

China Regenerative Medicine International Limited, an investment holding company, researches and develops bio-medical and healthcare products, and medical techniques. It operates through three segments: Tissue Engineering, Stem Cell, and Cosmetics and Healthcare. The company offers ActivSkin, a tissue-engineered skin product; Acellular Corneal Stroma for use in therapeutic lamellar keratoplasty; Calcined Bovine Bone, a protein-detracted bone substitute material for inducing natural bone regeneration; and Acellular Anal Fistula Repair Stroma for anal fistula disease. It also researches and develops Recombinant Human Acellular Dermal Matrix, which is targeted on and applied for second degree burns; Selective Acellular Skin for use as a wound dressing; Acellular Amniotic Membrane, an anti-adhesion agent for muscle and tender rebuilding operations; and Absorbable Dental Membrane for jawbone defect restoration, which are in Stage II business development process. In addition, the company provides Cell Sheet-Autologous Chondrocyte Implantation, a medical technique for repairing knee and other related cartilage damages; and produces and sells cellular and stem cell therapy products. Further, it develops various cosmetic and skin care products for anti-aging, whitening, spot removal, and other applications on skin revival under the ascara brand, as well as anti-aging and healthcare solutions, and anti-aging and other natural supplement products. Additionally, it offers contract research organization services of drug screening, drug efficacy, and toxicity assays in the pre-clinical drug development; and produces and distributes 3D perfusion bioreactors and related consumables. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Wanchai, Hong Kong.

520 Employees
Last Reported Date: 07/28/16
Founded in 1995

china regenerative medicine (8158) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $1.3M
Chairman of the Board and Compliance Officer
Total Annual Compensation: $406.0K
Compensation as of Fiscal Year 2016.

china regenerative medicine (8158) Key Developments

China Regenerative Medicine International Limited Management Changes

China Regenerative Medicine International Limited announced that with effect from 7 October 2016: (i) Mr. Wong Sai Hung executive Director and chairman of the Board of the company (the Chairman), will be re-designated from Chairman to vice-chairman of the Board (the Vice-Chairman). Mr. Wong will remain as executive Director of the company; and (ii) Professor Cui Zhanfeng will be appointed as the Chairman and non-executive Director of the company.

China Regenerative Medicine International Limited Enters into Collaboration Agreement with The University of Hong Kong and The Innovation and Technology Commission of HKSAR on Translational Research Project

The board of directors of China Regenerative Medicine International Limited (CRMI or the company, together with its subsidiaries, the group) announced that the company has entered into a collaboration agreement with The University of Hong Kong (HKU) and The Innovation and Technology Commission of HKSAR (ITC) on a translational research project entitled ‘Automated Bioreactors for Expanding and Monitoring Mesenchymal Stem Cells’. Principle terms: The Project is expected to be commenced on 1 October 2016 and completed on 30 September 2018. The estimated cost of the Project is approximately HKD 8,800,000, in which HKD 4,400,000 will be contributed by CRMI and the remaining HKD 4,400,000 will be contributed by the Hong Kong Government's Innovation and Technology Fund of ITC. Pursuant to the Collaboration Agreement, the Company shall hold all Intellectual Property Rights arouse from the project in its sole name. Pursuant to the Collaboration Agreement, HKU shall have full legal and equitable title and interest in any and all of the equipment being procured for the Project. The Steering Committee will be formed before commencement of the Project and shall compromise representatives from the Company and HKU. The committee shall meet at least once every three months throughout the duration of the Project. Key responsibilities of the Steering Committee include monitoring of the project progress, endorsement of progress reports and final report, and endorse the financial statements and the audited accounts of the Project. The Project is expected to result an advance automated bioreactor with certain specifications.

China Regenerative Medicine International Limited Announces Executive Changes

The board of directors of China Regenerative Medicine International Limited announced that with effect from September 14, 2016, Mr. Tam Man Kin will cease to be the chief financial officer of the company and Mr. Mui Chi Hung will be appointed as the chief financial officer of the company. Mr. Mui, aged 50, has over 20 years of experience in financing, auditing and accounting. Prior to joining the Company, Mr. Mui held various senior positions in a few listed groups and international accounting firms.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

8158 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8158.
View Industry Companies
 

Industry Analysis

8158

Industry Average

Valuation 8158 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 167.6x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 101.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHINA REGENERATIVE MEDICINE, please visit www.crmi.hk. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.